Drug | Tablet
Glipizide 5mg + Metformin 500mg
Type 2 diabetes mellitus in adults with inadequate glycaemic control on metformin alone; add-on therapy when fasting and post‑prandial glucose remain elevated despite diet and exercise.
Glipizide closes pancreatic beta‑cell ATP‑sensitive K+ (KATP; SUR1) channels, depolarising the cell and increasing Ca2+ influx to trigger insulin release. Metformin activates AMP‑activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and improving peripheral insulin sensitivity while decreasing intestinal glucose absorption.
Glucomust M 5/500 Tablet is usually taken 1 tablet once daily with breakfast or the main meal initially; if prescribed twice daily, take with breakfast and dinner to reduce gastrointestinal upset and hypoglycaemia. Swallow whole with water; do not skip meals after taking the 5mg glipizide/500mg metformin combination.
Common side effects of Glucomust M 5/500 Tablet may include:
Hypoglycaemia risk is higher with missed meals, heavy exercise, alcohol use, elderly patients, or renal impairment—carry fast‑acting glucose. Metformin component: monitor eGFR before start and periodically; dose review advised when eGFR 30–45 and avoid initiation; stop during dehydration, severe infection, or hypoxic states. Lactic acidosis warning—seek urgent care for rapid breathing, persistent vomiting, severe weakness, abdominal pain. Hepatic impairment increases lactic acidosis/hypoglycaemia risk. Pregnancy: insulin preferred for diabetes management; use only if clinician considers benefit > risk. Breastfeeding: metformin appears in milk in small amounts; glipizide may cause infant hypoglycaemia—medical advice required. Vitamin B12 deficiency can occur with long‑term metformin—periodic B12 assessment in anaemia/neuropathy.
